435 related articles for article (PubMed ID: 25743445)
1. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J
J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445
[TBL] [Abstract][Full Text] [Related]
2. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.
Merlini G; Planté-Bordeneuve V; Judge DP; Schmidt H; Obici L; Perlini S; Packman J; Tripp T; Grogan DR
J Cardiovasc Transl Res; 2013 Dec; 6(6):1011-20. PubMed ID: 24101373
[TBL] [Abstract][Full Text] [Related]
3. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
4. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.
Cortese A; Vita G; Luigetti M; Russo M; Bisogni G; Sabatelli M; Manganelli F; Santoro L; Cavallaro T; Fabrizi GM; Schenone A; Grandis M; Gemelli C; Mauro A; Pradotto LG; Gentile L; Stancanelli C; Lozza A; Perlini S; Piscosquito G; Calabrese D; Mazzeo A; Obici L; Pareyson D
J Neurol; 2016 May; 263(5):916-924. PubMed ID: 26984605
[TBL] [Abstract][Full Text] [Related]
5. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
6. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
7. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.
Gundapaneni BK; Sultan MB; Keohane DJ; Schwartz JH
Eur J Neurol; 2018 Mar; 25(3):464-468. PubMed ID: 29115008
[TBL] [Abstract][Full Text] [Related]
9. Cardiac involvement, morbidity and mortality in hereditary transthyretin amyloidosis because of p.Glu89Gln mutation.
Gospodinova M; Sarafov S; Chamova T; Kirov A; Todorov T; Nakov R; Todorova A; Denchev S; Tournev I
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):688-695. PubMed ID: 32740500
[TBL] [Abstract][Full Text] [Related]
10. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
11. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
12. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
15. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation.
Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H
Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540
[TBL] [Abstract][Full Text] [Related]
16. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
17. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C;
J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Grogan DR
J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
[TBL] [Abstract][Full Text] [Related]
19. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report.
Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M
Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280
[No Abstract] [Full Text] [Related]
20. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
